CD13 Antibody (B-F10): sc-65292

CD13 Antibody (B-F10) is a mouse monoclonal IgG1 antibody that detects CD13 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and flow cytometry (FCM). CD13, also known as aminopeptidase N, is a type II transmembrane glycoprotein predominantly expressed on myeloid cells, including monocytes, basophils, eosinophils, neutrophils, and various myeloid leukemias, as well as on certain epithelial cells, fibroblasts, and osteoclasts. CD13 functions as a zinc-binding metalloprotease, playing a crucial role in the digestion of peptides and the inactivation of regulatory peptides like enkephalins, which are important for pain modulation and stress response. CD13 presence is significant in cancer biology, as CD13 may enhance the invasive capacity and metastatic behavior of cancer cells, making CD13 a potential target for therapeutic intervention. Notably, CD13 activity can be inhibited by specific compounds that induce apoptosis in CD13-positive cancer cells, highlighting CD13′s role in tumor progression. Furthermore, basic fibroblast growth factor (bFGF) expression has been shown to upregulate CD13 in human melanoma cells by activating both the myeloid and epithelial CD13 promoters, indicating a complex regulatory mechanism that could be exploited for cancer treatment strategies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD13 Antibody (B-F10) References:

1. Progress in the development of aminopeptidase N (APN/CD13) inhibitors.  |  Xu, W. and Li, Q. 2005. Curr Med Chem Anticancer Agents. 5: 281-301. PMID: 15992355
2. Recent advance in aminopeptidase N (APN/CD13) inhibitor research.  |  Zhang, X., et al. 2011. Curr Med Chem. 18: 5011-21. PMID: 22050749
3. An anti-human CD13 monoclonal antibody that suppresses the suppressive function of Treg cells.  |  Zhang, K., et al. 2013. Monoclon Antib Immunodiagn Immunother. 32: 16-20. PMID: 23600500
4. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.  |  Azimi, A., et al. 2017. Cell Death Dis. 8: e3029. PMID: 29048432
5. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.  |  Schmidt, LH., et al. 2017. Lung Cancer. 113: 121-127. PMID: 29110838
6. The DNA repair kinase ATM regulates CD13 expression and cell migration.  |  Stevenson, LK., et al. 2024. Front Cell Dev Biol. 12: 1359105. PMID: 38933336
7. Anaplasma phagocytophilum invasin AipA interacts with CD13 to elicit Src kinase signaling that promotes infection.  |  Lind, MCH., et al. 2024. mBio. 15: e0156124. PMID: 39324816
8. Identification of LRP1+CD13+ human periosteal stem cells that require LRP1 for bone repair.  |  Jeong, Y., et al. 2024. JCI Insight. 9: PMID: 39405183
9. Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences.  |  Hoffmann, T., et al. 1993. FEBS Lett. 336: 61-4. PMID: 7903256
10. Myeloid antigen, CD13, CD14, and/or CD33 expression is restricted to certain lymphoid neoplasms.  |  Nakase, K., et al. 1996. Am J Clin Pathol. 105: 761-8. PMID: 8659452

The preferred CD13 antibody is CD13 Antibody (3D8): sc-13536.